anti-pd-1 drug nivolumab shows high and durable clinical activity in advanced melanoma
Published 11 years ago • 1.8K plays • Length 5:03Download video MP4
Download video MP3
Similar videos
-
1:27
dr. antoni ribas on anti-pd-1 agent lambrolizumab in advanced melanoma
-
6:51
success for ipilimumab and nivolumab combo in advanced melanoma
-
0:56
treating patients with melanoma who progressed on anti-pd-l1 with lenvatinib and pembrolizumab
-
3:06
comment: immunotherapy combo increases median survival in advanced melanoma
-
8:01
anti–pd-1 adjuvant therapy in melanoma
-
14:27
melanoma patient story: immunotherapy treatment (nivolumab/opdivo) | rich’s story (5 of 5)
-
1:24
unlocking the potential of cancer treatment with keytruda immunotherapy
-
6:56
all you need to know about pd-l1 by immunohistochemistry
-
6:19
should you treat melanoma with nivolumab and relatlimab (opdualag)?
-
6:07
pd-1 targeting immunotherapy mk-3475 has high, long-lasting activity against metastatic melanoma
-
34:37
immunotherapy - pd-1 and beyond - melanoma education symposium, patrick ott md phd
-
2:48
checkmate067 outcomes: nivolumab plus ipilimumab in advanced melanoma
-
8:28
success for ipilimumab and nivolumab combo in advanced melanoma
-
5:39
nivolumab plus ipilimumab in advanced melanoma
-
2:35
beyond anti-pd-1 and anti-ctla-4 in melanoma
-
32:38
anti- pd1 treatment in advanced melanoma
-
3:20
update in anti-ctla4 and anti-pd1 treatment in advanced melanoma
-
8:43
fianlimab and cemiplimab in patients with advanced melanoma
-
2:05
dr. jeffrey weber explores nivolumab in advanced melanoma
-
6:24
asco 2013: nivolumab blocking pd1 in lung cancer and melanoma
-
2:02
dr. jedd wolchok on concurrent ipilimumab and nivolumab in advanced melanoma
-
9:55
suzanne topalian: anti-pd-1 (bms-936558, mdx-1106) in advanced solid tumors